Saturday 17 October 2026 Export BGXXQ’s income statement to Excel — free account

Bright Green Corporation

BGXXQ Healthcare Drug Manufacturers Specialty & Generic

0.00 0.00 NaN

Follow BGXXQ

Alert me

Market cap: $13.9M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 60.56%

Capital & Financial Ratios $m

Market Cap 13.88

Revenue —

Net Income (9.03)

Free Cash Flow (1.64)

Net Debt 0.60

Current Ratio 0.01

Debt/Equity 0.07

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth —

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2021	2022	2023	Q'24
Cash	1	0	0	0
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	1	0	0	0

	2021	2022	2023	Q'24
Payables	0	5	4	5
ST’ Debt	—	—	—	1
Other	—	—	—	1
	0	8	6	7

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	—	0.00%
Earnings	—	—	0.00%
Book Value	—	—	14.94%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	(1)	0	—	—
’23	0	(2)	0	0	(2)
’22	0	(4)	(1)	2	(2)
’21	0	0	(1)	(1)	(2)
’20	—	—	—	(1)	(1)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	(1)	0	—	—
’23	(1)	(3)	0	0	(5)
’22	(1)	(5)	(4)	(3)	(13)
’21	0	0	(1)	(1)	(2)
’20	—	—	—	(1)	(1)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.01)	(0.01)	(0.01)	—	—
’23	(0.02)	(0.02)	(0.01)	(0.03)	(0.07)
’22	0.00	(0.12)	(0.04)	(0.01)	(0.17)
’21	0.00	0.00	0.00	(0.01)	(0.02)
’20	—	—	—	—	(0.02)

Fiscal quarters ending in the months shown.

Group	Line	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e
Price, $
Price, $	Low	—	—	—	—	—	—	—	—	0.35	0.22	Analyst estimates 2024–2026 Powerpack
	High	—	—	—	—	—	—	—	—	58.00	1.88
People
People	Employees	—	—	—	—	—	—	—	—	—	5
	Revenue/emp, $m	—	—	—	—	—	—	—	—	—	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	—	—	0.00	0.00	0.00	0.00	—
	EBT	—	—	—	—	—	(1)	(3)	(2)	(28)	(13)
	EBT margin, %	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	Net income	—	—	—	—	—	(1)	(3)	(2)	(28)	(13)
	Depreciation	—	—	—	—	—	1	1	1	1	1
Per share, $
Per share, $	Revenue	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	—	—	—	(0.01)	(0.02)	(0.02)	(0.17)	(0.07)
	Cash flow	—	—	—	—	—	0.00	0.00	(0.01)	(0.01)	(0.01)
	Capex	—	—	—	—	—	0.00	0.00	0.00	(0.06)	(0.01)
	Free cash flow	—	—	—	—	—	0.00	0.00	(0.01)	(0.08)	(0.03)
	Book value	—	—	—	—	—	0.05	0.05	0.05	0.07	0.06
	Shares, m	—	—	—	—	—	158	135	157	162	179
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	—	0	(1)	(2)	(2)	(2)
	Capex	—	—	—	—	—	—	—	0	(11)	(3)
	Free cash flow	—	—	—	—	—	0	(1)	(2)	(13)	(5)
Balance, $m
Balance, $m	Working capital	—	—	—	—	—	0	0	1	(7)	(6)
	Total debt	—	—	—	—	—	—	0	0	4	0
	Net debt	—	—	—	—	—	—	0	(1)	3	0
	Shareholders’ equity	—	—	—	—	—	8	7	8	12	11
Returns, %
Returns, %	ROA	—	—	—	—	—	0.00	(36.87)	(29.86)	(175.25)	(65.33)
	ROIC	—	—	—	—	—	0.00	(25.44)	(21.24)	(114.96)	(49.81)
	ROE	—	—	—	—	—	0.00	(38.87)	(32.26)	(279.43)	(116.46)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CPHI China Pharma Holdings, Inc.	$31.3M	— (loss-making)	— (loss-making)	−7.56% (below 0%: shrinking)	n/m	−113.57% (below 0%: shrinking)	8.82%	(150.99%)	Compare
SHPH Shuttle Pharmaceuticals Holdings, Inc.	$26.5M	0.2×	—	—	n/m	+82.01% (above 0%: growing)	0.00%	0.00%	Compare
TXMD TherapeuticsMD, Inc.	$22.3M	— (loss-making)	18.9×	−8.72% (below 0%: shrinking)	−80.00% (below 0%: shrinking)	+104.46% (above 0%: growing)	100.00%	(93.90%)	Compare
AYTU Aytu BioPharma, Inc.	$21.8M	— (loss-making)	— (loss-making)	+6.42% (above 0%: growing)	n/m	+57.72% (above 0%: growing)	64.63%	(4.82%)	Compare
UPC Universe Pharmaceuticals INC	$20.9M	— (loss-making)	4.1×	−23.98% (below 0%: shrinking)	−110.15% (below 0%: shrinking)	−84.99% (below 0%: shrinking)	32.57%	0.00%	Compare
BGXXQ Bright Green Corporation	$13.9M	— (loss-making)	—	—	n/m	−1.46% (below 0%: shrinking)	0.00%	0.00%
BFRI Biofrontera Inc.	$12.6M	— (loss-making)	— (loss-making)	+32.92% (above 0%: growing)	n/m	+45.57% (above 0%: growing)	79.92%	(4.37%)	Compare
INM InMed Pharmaceuticals Inc.	$7.3M	— (loss-making)	—	−26.22% (below 0%: shrinking)	n/m	−40.43% (below 0%: shrinking)	22.46%	0.00%	Compare
APUS Apimeds Pharmaceuticals US, Inc.	$6.6M	— (loss-making)	—	—	n/m	−67.94% (below 0%: shrinking)	—	0.00%	Compare
Median of peers	$21.3M	—	—	−8.14%	—	+2.57%	32.57%	(2.18%)